U.S. Markets closed

Salix, Pharming Group announces FDA approval of Ruconest

Salix Pharmaceuticals (SLXP) and Pharming Group NV (PHARM) announced that the FDA has approved Ruconest 50 IU/kg for the treatment of acute angioedema attacks in adult and adolescent patients with hereditary angioedema, or HAE. Because of the limited number of patients with laryngeal attacks, effectiveness was not established in HAE patients with laryngeal attacks.